Pfizer’s Upjohn Business Sees ‘Expected Drop’ Of 37%
Loss Of Exclusivity For Lyrica Cited As Main Factor
Despite reporting a 37% drop in Upjohn’s first-quarter sales, Pfizer has insisted that the decline was consistent with its expectations for the business. Meanwhile, biosimilars sales have been boosted by US launches as sterile injectables and hospital medicines have seen a lift from COVID-19.
